Physician profile
Willard Whitehead
NPI 1386657336
$2,015.95
in general payments reported to CMS, 2019-2025
16 companies · $83.18 in 2025
The $83.18 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,107 · 2020: $459 · 2021: $23.92 · 2022: $137 · 2023: $45.67 · 2024: $159 · 2025: $83.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $288.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $469.19 | 2019-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $290.40 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $273.21 | 2019-2022 | |
| Allergan, INC. | $249.73 | 2019-2020 | |
| Indivior INC. | $190.94 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $115.69 | 2019-2025 | Uzedy |
| Axsome Therapeutics, INC. | $98.61 | 2024 | Auvelity |
| Harmony Biosciences LLC | $75.06 | 2020 | |
| Neurocrine Biosciences, INC. | $54.52 | 2019 | |
| Ironshore Pharmaceuticals INC. | $51.90 | 2019 | |
| Vanda Pharmaceuticals INC. | $33.79 | 2019 | |
| Alkermes, INC. | $32.45 | 2023-2024 | Lybalvi |
| Abbvie INC. | $30.52 | 2023 | Vraylar |
| Avanir Pharmaceuticals, INC. | $19.96 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.25 | 2024 | Caplyta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $13.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willard Whitehead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.